Generate Biomedicines, Inc. Common Stock(GENB)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$12.07
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for GENB

11/13/2026: GENB (1-star) is currently NOT-A-BUY. Pass it for now.

Generate Biomedicines is a clinical-stage biotechnology company that utilizes artificial intelligence and machine learning through its proprietary Generate Platform to design novel protein therapeutics. The company's primary strengths lie in its advanced computational platform, substantial cash reserves following its early 2026 initial public offering, and strategic partnerships with major pharmaceutical leaders. Its core growth story centers on advancing an internal pipeline of engineered candidates across oncology, immunology, and metabolic diseases. However, the company faces notable financial and execution risks, including ongoing net losses, an absence of approved commercial products, and the inherent clinical attrition rates of drug development. The stock is best suited for growth-oriented investors with high risk tolerance who are willing to monitor upcoming clinical readouts and partnership developments.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company offers high-growth exposure to the burgeoning intersection of artificial intelligence and biotechnology drug development.
Momentum investorStrong fit while signal remains positiveTrading momentum is heavily influenced by clinical milestone announcements, partnership updates, and broader biotech sentiment.
Value investorWeak fitThe company lacks current earnings, positive cash flow, or traditional valuation metrics due to its clinical-stage status.
Dividend investorWeak fitAs a clinical-stage biotechnology firm, all capital is retained to fund research and development rather than distributed as dividends.
Low-risk investorWeak fitHigh clinical trial uncertainties, lack of commercial products, and market volatility present significant risk profiles.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighBiotech equities frequently experience sharp price swings driven by clinical trial readouts and market sentiment.
Valuation riskMedium / highValuation relies heavily on future discounted cash flows from pipeline assets that carry high clinical failure rates.
Competition risk (AI drug discovery competition)HighRapid technological advances by peers and well-capitalized legacy pharma can disrupt market positioning.
Business qualityMediumWhile the technological platform is sophisticated, the business model remains unproven commercially without approved drugs.
Dividend incomeLow / noneThe company pays no dividend and focuses entirely on capital appreciation and pipeline reinvestment.
Execution riskHighSuccess depends entirely on successfully executing clinical trials and validating AI-designed protein targets in humans.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.56B USD
Price to earnings Ratio -
1Y Target Price 27
Price to earnings Ratio -
1Y Target Price 27
Volume (30-day avg) 979.2K shares
Beta -
52 Weeks Range 11.00 - 22.67
Updated Date 11/15/2026
52 Weeks Range 11.00 - 22.67
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -2.44

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -50.81%
Avg. Invested days 12
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
GENB receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by soft unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
GENB has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, strong revenue growth (+55.9%) is partially offset by negative earnings growth (-16.9%), weak cash generation (FCF margin -640.1%), weak profitability (net margin -637.0%).

Financial Health Rating

★★★★★
GENB's financial health is supported by moderate efficiency, including operating-expense and cost-of-revenue discipline (opex 837.0% of revenue). Cash strength is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is GENB's strongest growth driver at +55.9% FY2025 versus FY2024 (strong, 5 stars). By comparison, while earnings growth (-16.9%, negative) and free-cash-flow growth (-68.4%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 82.5% and approximately 47.4% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 14.12% supports management-shareholder alignment.

Top 5 Institutional Investors

Flagship Ventures Management, Inc. 48.55%
FMR Inc 4.04%
Capital World Investors 3.27%
BRAIDWELL LP 2.54%
T. Rowe Price Associates, Inc. 1.67%

Unit Economics (Per $1K Revenue)

★★★★★
GENB generates approximately $1,000 of gross profit, $-7,370 of operating income, and $-6,401 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 2-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 8.82%

Quantitative Style Profile

★★★★★
GENB has a relatively low-volatility profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskShort Squeeze Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Collaboration and Licensing AgreementsUpfront payments, research funding, and clinical milestone fees from major pharmaceutical partnerships like Novartis and Zealand Pharma.Revenue currently stems from validating the AI platform with partners rather than direct commercial drug sales.
Future Proprietary TherapeuticsAnticipated commercial sales and royalties from internally developed oncology, immunology, and metabolic pipeline assets.Long-term value creation depends heavily on successfully bringing wholly-owned drugs to market.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 1.16B
Price to Sales(TTM) 73.96
Enterprise Value 1.16B
Price to Sales(TTM) 73.96
Enterprise Value to Revenue 43.88
Enterprise Value to EBITDA -
Shares Outstanding 129.10M
Shares Floating 61.20M
Shares Outstanding 129.10M
Shares Floating 61.20M
Percent Insiders 14.12
Percent Institutions 82.45

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.